Source link : https://www.newshealth.biz/health-news/zenocutuzumab-effective-against-nrg1-fusion-cancers/
TOPLINE: Zenocutuzumab demonstrates efficacy in patients with Neuregulin 1 (NRG1) fusion–positive cancer, achieving a 30% response rate across multiple tumor types. The bispecific antibody shows particularly promising results in non–small cell lung cancer (NSCLC) and pancreatic cancer patients, with responses lasting a median of 11.1 months. METHODOLOGY: The US Food and Drug Administration (FDA) approved […]
Author : News Health
Publish date : 2025-02-07 12:14:56
Copyright for syndicated content belongs to the linked Source.